Hepatocellular carcinoma

Bubu A. Banini; Lewis Rowland Roberts

doi:10.1007/978-3-319-13614-1_22

Hepatocellular carcinoma

Bubu A. Banini, Lewis Rowland Roberts

Gastroenterology and Hepatology

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Hepatocellular carcinoma (HCC) is the second most common cause of cancer-related deaths worldwide, with an estimated 782,000 new cases and 746,000 deaths from HCC in 2012 alone. The highest rates of HCC occur in Southeast Asia and sub-Saharan Africa, where the primary etiology is hepatitis B virus infection. Over the past few decades, Europe and the USA have also experienced substantial increases in HCC incidence and mortality mainly as a result of hepatitis C virus-associated cirrhosis. In many patients, the coexistence of HCC and cirrhosis complicates prognostic assessment and treatment. In this chapter, we provide an overview of the pathophysiology of HCC, recommendations for screening and diagnosis, and an up-to-date summary of the current therapies and future directions in management of this complex disease.

Original language	English (US)
Title of host publication	Complications of Cirrhosis: Evaluation and Management
Publisher	Springer International Publishing
Pages	207-218
Number of pages	12
ISBN (Print)	9783319136141, 9783319136134
DOIs	https://doi.org/10.1007/978-3-319-13614-1_22
State	Published - Jan 1 2015

Keywords

BCLC staging
Liver transplantation
Radiofrequency ablation
Sorafenib
Transarterial chemoembolization
Transarterial radioembolization

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1007/978-3-319-13614-1_22

Cite this

@inbook{532c1054a5144d4893629c2713a489fb,

title = "Hepatocellular carcinoma",

abstract = "Hepatocellular carcinoma (HCC) is the second most common cause of cancer-related deaths worldwide, with an estimated 782,000 new cases and 746,000 deaths from HCC in 2012 alone. The highest rates of HCC occur in Southeast Asia and sub-Saharan Africa, where the primary etiology is hepatitis B virus infection. Over the past few decades, Europe and the USA have also experienced substantial increases in HCC incidence and mortality mainly as a result of hepatitis C virus-associated cirrhosis. In many patients, the coexistence of HCC and cirrhosis complicates prognostic assessment and treatment. In this chapter, we provide an overview of the pathophysiology of HCC, recommendations for screening and diagnosis, and an up-to-date summary of the current therapies and future directions in management of this complex disease.",

keywords = "BCLC staging, Liver transplantation, Radiofrequency ablation, Sorafenib, Transarterial chemoembolization, Transarterial radioembolization",

author = "Banini, {Bubu A.} and Roberts, {Lewis Rowland}",

year = "2015",

month = jan,

day = "1",

doi = "10.1007/978-3-319-13614-1_22",

language = "English (US)",

isbn = "9783319136141",

pages = "207--218",

booktitle = "Complications of Cirrhosis: Evaluation and Management",

publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Hepatocellular carcinoma

AU - Banini, Bubu A.

AU - Roberts, Lewis Rowland

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Hepatocellular carcinoma (HCC) is the second most common cause of cancer-related deaths worldwide, with an estimated 782,000 new cases and 746,000 deaths from HCC in 2012 alone. The highest rates of HCC occur in Southeast Asia and sub-Saharan Africa, where the primary etiology is hepatitis B virus infection. Over the past few decades, Europe and the USA have also experienced substantial increases in HCC incidence and mortality mainly as a result of hepatitis C virus-associated cirrhosis. In many patients, the coexistence of HCC and cirrhosis complicates prognostic assessment and treatment. In this chapter, we provide an overview of the pathophysiology of HCC, recommendations for screening and diagnosis, and an up-to-date summary of the current therapies and future directions in management of this complex disease.

AB - Hepatocellular carcinoma (HCC) is the second most common cause of cancer-related deaths worldwide, with an estimated 782,000 new cases and 746,000 deaths from HCC in 2012 alone. The highest rates of HCC occur in Southeast Asia and sub-Saharan Africa, where the primary etiology is hepatitis B virus infection. Over the past few decades, Europe and the USA have also experienced substantial increases in HCC incidence and mortality mainly as a result of hepatitis C virus-associated cirrhosis. In many patients, the coexistence of HCC and cirrhosis complicates prognostic assessment and treatment. In this chapter, we provide an overview of the pathophysiology of HCC, recommendations for screening and diagnosis, and an up-to-date summary of the current therapies and future directions in management of this complex disease.

KW - BCLC staging

KW - Liver transplantation

KW - Radiofrequency ablation

KW - Sorafenib

KW - Transarterial chemoembolization

KW - Transarterial radioembolization

UR - http://www.scopus.com/inward/record.url?scp=84944561250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944561250&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-13614-1_22

DO - 10.1007/978-3-319-13614-1_22

M3 - Chapter

AN - SCOPUS:84944561250

SN - 9783319136141

SN - 9783319136134

SP - 207

EP - 218

BT - Complications of Cirrhosis: Evaluation and Management

PB - Springer International Publishing

ER -

Hepatocellular carcinoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this